Crinetics Pharmaceuticals Shares Outstanding History (CRNX)
Crinetics Pharmaceuticals reported 95.6M shares outstanding at the end of fiscal 2025.
View full Crinetics Pharmaceuticals company overviewCrinetics Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 95.6M | 2.6M | +2.85% |
| 2024 | 2024-12-31 | 92.9M | 24.8M | +36.31% |
| 2023 | 2023-12-31 | 68.2M | 14.3M | +26.54% |
| 2022 | 2022-12-31 | 53.9M | 6.3M | +13.19% |
| 2021 | 2021-12-31 | 47.6M | 14.6M | +44.23% |
| 2020 | 2020-12-31 | 33.0M | 8.7M | +36.01% |
| 2019 | 2019-12-31 | 24.3M | 24.2M | +100739.53% |
| 2018 | 2018-12-31 | 24,061 | −1.5M | −98.45% |
| 2017 | 2017-12-31 | 1.5M | — | — |
Crinetics Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 105.8M | 11.7M | +12.41% |
| Q1 2026 | 2026-03-31 | 105.3M | 11.8M | +12.61% |
| Q4 2025 | 2025-12-31 | 95.6M | 2.6M | +2.85% |
| Q3 2025 | 2025-09-30 | 94.5M | 13.7M | +16.96% |
| Q2 2025 | 2025-06-30 | 94.1M | 14.8M | +18.66% |
| Q1 2025 | 2025-03-31 | 93.5M | 15.0M | +19.08% |
| Q4 2024 | 2024-12-31 | 92.9M | 24.8M | +36.31% |
| Q3 2024 | 2024-09-30 | 80.8M | 14.1M | +21.19% |
| Q2 2024 | 2024-06-30 | 79.3M | 47.0M | +145.24% |
| Q1 2024 | 2024-03-31 | 78.5M | 23.9M | +43.63% |
| Q4 2023 | 2023-12-31 | 68.2M | 14.2M | +26.27% |
| Q3 2023 · Sep 30 | 2023-09-30 | 66.7M | 12.8M | +23.82% |
| Q3 2023 · Aug 31 | 2023-08-31 | 32.3M | −21.5M | −39.88% |
| Q2 2023 | 2023-06-30 | 54.7M | 962,000 | +1.79% |
| Q1 2023 | 2023-03-31 | 54.0M | 6.2M | +12.95% |
| Q4 2022 | 2022-12-31 | 53.9M | 6.3M | +13.19% |
| Q3 2022 | 2022-09-30 | 53.8M | 15.2M | +39.30% |
| Q2 2022 | 2022-06-30 | 53.7M | 16.0M | +42.57% |
| Q1 2022 | 2022-03-31 | 47.8M | 14.8M | +44.78% |
| Q4 2021 | 2021-12-31 | 47.6M | 14.6M | +44.23% |
| Q3 2021 | 2021-09-30 | 38.6M | 5.7M | +17.31% |
| Q2 2021 | 2021-06-30 | 37.7M | 4.8M | +14.59% |
| Q1 2021 | 2021-03-31 | 33.0M | 8.4M | +34.29% |
| Q4 2020 | 2020-12-31 | 33.0M | 8.7M | +36.01% |
| Q3 2020 | 2020-09-30 | 32.9M | 8.7M | +35.94% |
| Q2 2020 | 2020-06-30 | 32.9M | 8.7M | +35.90% |
| Q1 2020 | 2020-03-31 | 24.6M | 472,000 | +1.96% |
| Q4 2019 | 2019-12-31 | 24.3M | 202,000 | +0.84% |
| Q3 2019 | 2019-09-30 | 24.2M | 183,012 | +0.76% |
| Q2 2019 | 2019-06-30 | 24.2M | 21.9M | +932.05% |
| Q1 2019 | 2019-03-31 | 24.1M | 22.6M | +1456.23% |
| Q4 2018 | 2018-12-31 | 24.1M | — | — |
| Q3 2018 | 2018-09-30 | 24.0M | — | — |
| Q2 2018 | 2018-06-30 | 2.3M | — | — |
| Q4 2017 | 2017-12-31 | 1.5M | — | — |
Crinetics Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Crinetics Pharmaceuticals's shares outstanding moved from 33.0M to 95.6M, a change of 62.6M. The latest reported quarter, Q2 2026, shows 105.8M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Crinetics Pharmaceuticals filings at SEC.gov ↗